dcsimg

    • 3003新葡的京集团

    PHIP
     
    Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
    YOU SHOULD READ THE WARNING IN THE DOCUMENT.
     
    ► Warning
    ► Important
    ► Expected Timetable
    ► Contents
    ► Summary
    ► Definitions
    ► Glossary of Technical Terms
    ► Forward-looking Statements
    ► Risk Factors
    ► Waivers and Consents from Strict Compliance with the Hong Kong Listing Rules
    ► Information about this Document and the [REDACTED]
    ► Directors, Supervisors and Parties Involved in the [REDACTED]
    ► Corporate Information
    ► Industry Overview
    ► Regulatory Environment
    ► History, Development and Corporate Structure
    ► Business
    ► Relationship with the Controlling Shareholders
    ► Connected Transaction
    ► Directors, Supervisors and Senior Management
    ► Share Capital
    ► Substantial Shareholders
    ► [REDACTED]
    ► Financial Information
    ► Future Plans and Use of [REDACTED]
    ► [REDACTED]
    ► Structure of the [REDACTED]
    ► How to Apply for the [REDACTED]
    ► Appendix I - Accountants' Report
    ► Appendix IA - Report on Review of Interim Condensed Consolidated Financial Information for the Three Months Ended March 31, 2020
    ► Appendix II - [REDACTED]
    ► Appendix III - Taxation and Foreign Exchange
    ► Appendix IV - Summary of Principal Legal and Regulatory Provisions
    ► Appendix V - Summary of Articles of Association
    ► Appendix VI - Statutory and General Information
    ► Appendix VII - Documents Delivered to the Registrar of Companies in Hong Kong and Available for Inspection